Akari Therapeutics Plc Stock Investor Sentiment

AKTX Stock  USD 1.21  0.09  8.04%   
Slightly above 71 percent of all Akari Therapeutics' investors are curious in acquiring. The analysis of overall sentiment of trading Akari Therapeutics PLC stock suggests that a large number of investors are confidant at this time. Akari Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Akari Therapeutics' earnings reports, geopolitical events, and overall market trends.
  

Akari Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Akari Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a week ago at www.macroaxis.com         
Insider Trading
Macroaxis News
over a week ago at gurufocus.com         
Akari Therapeutics Regains Full Nasdaq Compliance
Gurufocus Stories at Macroaxis
over two weeks ago at news.google.com         
This Akari Therapeutics Insider Increased Their Holding By 69 percent Last Year - Yahoo Finance
Google News at Macroaxis
over two weeks ago at globenewswire.com         
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
Macroaxis News: globenewswire.com
over two weeks ago at globenewswire.com         
Acquisition by Patel Samir Rashmikant of 1404622000 shares of Akari Therapeutics subject to Rule 16b...
Macroaxis News: globenewswire.com
over three weeks ago at news.google.com         
Akari Therapeutics shareholders approve Peak Bio merger - Investing.com
Google News at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Patel Samir Rashmikant of 79684000 shares of Akari Therapeutics at 0.0013 subject to ...
Macroaxis News
over a month ago at thelincolnianonline.com         
Akari Therapeutics Stock Passes Below 200 Day Moving Average Whats Next?
news
over a month ago at thelincolnianonline.com         
Akari Therapeutics Earns Sell Rating from Analysts at StockNews.com
news
over a month ago at www.macroaxis.com         
Disposition of 1300000 shares by Grissinger Michael of Akari Therapeutics at 0.0218 subject to Rule ...
Macroaxis News
over a month ago at thelincolnianonline.com         
Akari Therapeutics Earns Sell Rating from Analysts at StockNews.com
news
over two months ago at www.macroaxis.com         
Disposition of tradable shares by Williams Donald A of Akari Therapeutics subject to Rule 16b-3
Macroaxis News
over two months ago at www.macroaxis.com         
Acquisition by Patel Samir Rashmikant of 175080000 shares of Akari Therapeutics at 0.0015 subject to...
Macroaxis News
over two months ago at news.google.com         
Akari Therapeutics appoints Rob Bazemore to board By Investing.com - Investing.com Canada
Google News at Macroaxis
over two months ago at finance.yahoo.com         
Insider Trading
Yahoo News
Far too much social signal, news, headlines, and media speculation about Akari Therapeutics that are available to investors today. That information is available publicly through Akari media outlets and privately through word of mouth or via Akari internal channels. However, regardless of the origin, that massive amount of Akari data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Akari Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Akari Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Akari Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Akari Therapeutics alpha.

Akari Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Discretionary transaction by Prudo-chlebosz Raymond of 9210500 shares of Akari Therapeutics at 0.03 subject to Rule 16b-3
09/10/2024
2
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
09/17/2024
3
Acquisition by Patel Samir Rashmikant of 175080000 shares of Akari Therapeutics at 0.0015 subject to Rule 16b-3
09/30/2024
4
Disposition of tradable shares by Williams Donald A of Akari Therapeutics subject to Rule 16b-3
10/01/2024
5
Disposition of 1300000 shares by Grissinger Michael of Akari Therapeutics at 0.0218 subject to Rule 16b-3
10/08/2024
6
Acquisition by Patel Samir Rashmikant of 79684000 shares of Akari Therapeutics at 0.0013 subject to Rule 16b-3
10/31/2024
7
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
11/14/2024
8
Insider Trading
11/22/2024

Additional Tools for Akari Stock Analysis

When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.